{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:25:34Z","timestamp":1794471934346,"version":"4.9.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neo.2025.101224","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T19:27:30Z","timestamp":1756841250000},"page":"101224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Contribution of the immune bone marrow microenvironment to tumor growth and bone deconstruction: implications for improving immunotherapeutic strategies in bone metastasis"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4842-8618","authenticated-orcid":false,"given":"E.","family":"Massy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9318-6785","authenticated-orcid":false,"given":"C.B.","family":"Confavreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Point","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bonnelye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4463","authenticated-orcid":false,"given":"P.","family":"Cl\u00e9zardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101224_bib0001","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: mechanisms, therapies, and biomarkers","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neo.2025.101224_bib0002","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/s41416-021-01329-6","article-title":"Bone marrow niches in the regulation of bone metastasis","volume":"124","author":"Chen","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0003","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41591-024-03215-z","article-title":"A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features","volume":"30","author":"Klughammer","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2025.101224_bib0004","doi-asserted-by":"crossref","first-page":"8353","DOI":"10.1038\/s41467-023-43458-x","article-title":"High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis","volume":"14","author":"Janesick","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101224_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2025.100888","article-title":"Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization","author":"Liu","year":"2025","journal-title":"Cell Genom."},{"key":"10.1016\/j.neo.2025.101224_bib0006","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1152\/physrev.00036.2016","article-title":"Osteoimmunology: the conceptual framework unifying the immune and skeletal systems","volume":"97","author":"Okamoto","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neo.2025.101224_bib0007","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neo.2025.101224_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00018.2019","article-title":"Immunity, Hypoxia, and Metabolism-the M\u00e9nage \u00e0 Trois of cancer: implications for immunotherapy","volume":"100","author":"Riera-Domingo","year":"2020","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neo.2025.101224_bib0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00262-018-2170-8","article-title":"How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions","volume":"68","author":"Bruger","year":"2019","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.neo.2025.101224_bib0011","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-12-2202","article-title":"Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer","volume":"73","author":"Sawant","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101224_bib0012","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1172\/JCI92466","article-title":"Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone","volume":"128","author":"Roca","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neo.2025.101224_bib0013","doi-asserted-by":"crossref","first-page":"29087","DOI":"10.1074\/jbc.M109.035899","article-title":"Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone","volume":"284","author":"Lu","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2025.101224_bib0014","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2402903121","article-title":"Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization","volume":"121","author":"Yu","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U S. A"},{"key":"10.1016\/j.neo.2025.101224_bib0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0016","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-020-02527-6","article-title":"Neutrophils are mediators of metastatic prostate cancer progression in bone","volume":"69","author":"Costanzo-Garvey","year":"2020","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.neo.2025.101224_bib0017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bone.2018.01.004","article-title":"Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers","volume":"108","author":"Chambard","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.neo.2025.101224_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.07.007","article-title":"CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases","author":"Shi","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2025.101224_bib0019","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.neo.2025.101224_bib0020","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s12282-021-01270-9","article-title":"CD1a- and CD83-positive dendritic cells as prognostic markers of metastasis development in early breast cancer patients","volume":"28","author":"Giorello","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0021","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.4049\/jimmunol.1101855","article-title":"Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells","volume":"189","author":"Sawant","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.neo.2025.101224_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12258","article-title":"Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models","volume":"7","author":"Bottos","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2025.101224_bib0023","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2025.101224_bib0024","article-title":"Natural killer cell regulation of breast cancer stem cells mediates metastatic dormancy","author":"Bushnell","year":"2023","journal-title":"Cancer Biology;"},{"key":"10.1016\/j.neo.2025.101224_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41577-020-00452-4","article-title":"Silva-Santos B. \u03b3\u03b4 T cells in tissue physiology and surveillance","volume":"21","author":"Ribot","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neo.2025.101224_bib0026","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","article-title":"\u03b3\u03b4 T cells: pleiotropic immune effectors with therapeutic potential in cancer","volume":"19","author":"Silva-Santos","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0027","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1158\/1078-0432.CCR-12-0918","article-title":"In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger V\u03b39V\u03b42 T-cell antitumor cytotoxicity through ICAM-1 engagement","volume":"18","author":"Benza\u00efd","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101224_bib0028","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","article-title":"High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo","volume":"71","author":"Benza\u00efd","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101224_bib0029","doi-asserted-by":"crossref","first-page":"eadf0108","DOI":"10.1126\/sciadv.adf0108","article-title":"\u03b3\u03b4-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer","volume":"9","author":"Frieling","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neo.2025.101224_bib0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.molmed.2003.10.001","article-title":"T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity","volume":"9","author":"Schirrmacher","year":"2003","journal-title":"Trends. Mol. Med."},{"key":"10.1016\/j.neo.2025.101224_bib0031","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2005.01.008","article-title":"Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells","volume":"22","author":"Mazo","year":"2005","journal-title":"Immunity. Elsevier BV;"},{"key":"10.1016\/j.neo.2025.101224_bib0032","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/0008-5472.CAN-10-3922","article-title":"CD8+ T cells regulate bone tumor burden independent of osteoclast resorption","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101224_bib0033","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/jbmr.4615","article-title":"Bone microenvironment-suppressed T cells increase osteoclast formation and osteolytic bone metastases in mice","volume":"37","author":"Arellano","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.neo.2025.101224_bib0034","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09707","article-title":"Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling","volume":"470","author":"Tan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101224_bib0035","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s12094-018-02023-5","article-title":"The RANK-RANKL axis: an opportunity for drug repurposing in cancer?","volume":"21","author":"Peters","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0036","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s42255-019-0104-1","article-title":"Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone","volume":"1","author":"Asano","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.neo.2025.101224_bib0037","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4161\/onci.1.2.18480","article-title":"Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer","volume":"1","author":"Zhao","year":"2012","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.neo.2025.101224_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068171","article-title":"T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. Gao J-X, editor","volume":"8","author":"Monteiro","year":"2013","journal-title":"PLoS. One"},{"key":"10.1016\/j.neo.2025.101224_bib0039","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157340","article-title":"The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cell homing to bone","volume":"132","author":"Pal","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neo.2025.101224_bib0040","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.neo.2025.101224_bib0041","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev-immunol-101220-015603","article-title":"B cell function in the tumor microenvironment","volume":"40","author":"Downs-Canner","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neo.2025.101224_bib0042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.molimm.2020.01.008","article-title":"PD-L1+ regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis","volume":"119","author":"Wu","year":"2020","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.neo.2025.101224_bib0043","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.12-7-873","article-title":"Tremelimumab (CP-675,206), a cytotoxic T lymphocyte\u2013associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer","volume":"12","author":"Ribas","year":"2007","journal-title":"The Oncologist"},{"key":"10.1016\/j.neo.2025.101224_bib0044","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101224_bib0045","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101224_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.06.013","article-title":"Immunotherapy for metastatic renal cell carcinoma: a brief history, current trends, and future directions","author":"Rambhia","year":"2021","journal-title":"Urologic Oncol.: Semin. Orig. Investig."},{"key":"10.1016\/j.neo.2025.101224_bib0047","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0048","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2025.101224_bib0049","doi-asserted-by":"crossref","DOI":"10.1093\/jbmr\/zjaf055","article-title":"Programmed cell death protein 1 (PD-1) blockade regulates skeletal remodeling in a sex- and age-dependent manner","author":"Joseph","year":"2025","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.neo.2025.101224_bib0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0051","article-title":"Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors","volume":"3","author":"Ye","year":"2024","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0052","doi-asserted-by":"crossref","first-page":"eaav3937","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non\u2013small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.neo.2025.101224_bib0053","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.neo.2025.101224_bib0054","doi-asserted-by":"crossref","first-page":"7684","DOI":"10.18632\/oncotarget.23969","article-title":"Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis","volume":"9","author":"Lan","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2025.101224_bib0055","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225036","article-title":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0056","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0057","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-020-02613-9","article-title":"Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \u2265\u200950","volume":"69","author":"Cortellini","year":"2020","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.neo.2025.101224_bib0058","doi-asserted-by":"crossref","first-page":"915","DOI":"10.6004\/jnccn.2020.7668","article-title":"Bone metastases, skeletal-related events, and survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"19","author":"Qin","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.neo.2025.101224_bib0059","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10637-019-00882-5","article-title":"Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study","volume":"38","author":"Kawachi","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.neo.2025.101224_bib0060","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cllc.2021.03.005","article-title":"PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"22","author":"Dall\u2019Olio","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0061","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1111\/1759-7714.13597","article-title":"Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"11","author":"Li","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0062","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2022.03.006","article-title":"Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays \u201ccold\u201d immune characteristics in Non-small cell lung cancer","volume":"166","author":"Zhu","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0063","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0064","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","article-title":"Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors","volume":"78","author":"Fizazi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.neo.2025.101224_bib0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0066","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1158\/1078-0432.CCR-21-0063","article-title":"A Phase Ib study of atezolizumab with Radium-223 dichloride in men with metastatic castration-resistant prostate cancer","volume":"27","author":"Fong","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101224_bib0067","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0068","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2025.101224_bib0069","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101224_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010674","article-title":"Determinants of 5-year survival in patients with advanced NSCLC with PD-L1\u226550% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry","volume":"13","author":"Cortellini","year":"2025","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0071","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2025.101224_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1030147","article-title":"Pires Da Silva I. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy","volume":"13","author":"Conway","year":"2022","journal-title":"Front. Immunol."},{"issue":"25","key":"10.1016\/j.neo.2025.101224_bib0073","article-title":"Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts","volume":"S1535-6108","author":"Cheng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2025.101224_bib0074","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1158\/0008-5472.CAN-13-3334","article-title":"Osteopontin Shapes Immunosuppression in the Metastatic Niche","volume":"74","author":"Sangaletti","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2025.101224_bib0075","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0076","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41571-018-0095-y","article-title":"Teng MWL. Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy","volume":"15","author":"Ahern","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101224_bib0077","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12885-018-4412-8","article-title":"PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0078","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0000000000000459","article-title":"Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center","volume":"28","author":"Afzal","year":"2018","journal-title":"Melanoma Res."},{"key":"10.1016\/j.neo.2025.101224_bib0079","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.neo.2025.101224_bib0080","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.neo.2025.101224_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113984","article-title":"The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations","volume":"202","author":"Schaper-Gerhardt","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107858","article-title":"Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases","volume":"193","author":"Asano","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0083","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.21037\/jtd-21-150","article-title":"Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors","volume":"13","author":"Cao","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.neo.2025.101224_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109030","article-title":"Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer","volume":"110","author":"Zheng","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neo.2025.101224_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697298","article-title":"Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio","volume":"12","author":"Bongiovanni","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2025.101224_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107417","article-title":"High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors","volume":"186","author":"Manglaviti","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.neo.2025.101224_bib0087","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.neo.2025.101224_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2024.100634","article-title":"Synergistic effect between denosumab and immune checkpoint inhibitors (ICI)? A retrospective study of 268 patients with ICI and bone metastases","volume":"48","author":"Mabrut","year":"2024","journal-title":"J. Bone Oncol."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625001034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:02:53Z","timestamp":1760140973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625001034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":88,"alternative-id":["S1476558625001034"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101224","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contribution of the immune bone marrow microenvironment to tumor growth and bone deconstruction: implications for improving immunotherapeutic strategies in bone metastasis","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101224"}}